EJE PRIZE 2017: Hypothalamic AMPK: a golden target against obesity?

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
hypoglycemia 1 endocrinologydiseases
metformin 6 endocrinologydiseasesdrugs
obesity 12 endocrinologydiseases
pioglitazone 1 endocrinologydiseasesdrugs
rosiglitazone 1 endocrinologydiseasesdrugs
Liraglutide 1 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Liraglutide 19870 exendin-4), have been designed to mimic the action of GLP-1 to increase insulin sensitivity ([96]). Liraglutide has been reported to have opposing effects on AMPK. Although it increases AMPK phosphorylation in endothelium
metformin 1025 potential anti-obesity and/or antidiabetic effects, some currently in clinical use, such as nicotine, metformin and liraglutide are known to act through AMPK, either peripherally or centrally. Furthermore, the orexigenic
metformin 19113 LKB1-null animals do not have reduced levels of glucose ([18], [91]). Recent reports have also shown that metformin exerts its AMPK-independent effects in the liver ([92]). In contrast, mice with acetyl-CoA carboxylase
metformin 19302 acetyl-CoA carboxylase (ACC) mutations are refractory to the lipid and glucose-reducing effects of metformin ([93]). In addition to metformin, thiazolidinedione compounds, such as rosiglitazone and pioglitazone,
metformin 19335 mutations are refractory to the lipid and glucose-reducing effects of metformin ([93]). In addition to metformin , thiazolidinedione compounds, such as rosiglitazone and pioglitazone, also produce a dramatic increase
metformin 22803 has been suggested as a possible therapy in cancer. Indeed, evidence suggests that the AMPK activator metformin can reduce the tumor size ([89]). In contrast, high levels of pACC have been found in prostate cancer
metformin 24720 Activation of AMPK in peripheral organs is one of the mechanisms of the widely used antidiabetic drug, metformin (for an extensive review see ([87]). However, central activation of AMPK would not give the best outcome
pioglitazone 19401 metformin ([93]). In addition to metformin, thiazolidinedione compounds, such as rosiglitazone and pioglitazone , also produce a dramatic increase in AMP in skeletal muscle, which results in a rapid activation of
rosiglitazone 19383 glucose-reducing effects of metformin ([93]). In addition to metformin, thiazolidinedione compounds, such as rosiglitazone and pioglitazone, also produce a dramatic increase in AMP in skeletal muscle, which results in a rapid
Select Disease Character Offset Disease Term Instance
hypoglycemia 7781 activated in situations that lead to a reduction in intracellular energy levels, such as hypoxia and hypoglycemia , or to those that increase ATP utilization, such as muscle contraction or food deprivation ([1], [2],
obesity 99 Title: European Journal of EndocrinologyEJE PRIZE 2017: Hypothalamic AMPK: a golden target against obesity ?Alternative Title: M LópezAlternative Title: Hypothalamic AMPK and obesityMiguel LópezPublication
obesity 175 a golden target against obesity?Alternative Title: M LópezAlternative Title: Hypothalamic AMPK and obesity Miguel LópezPublication date (collection): 2/2017Publication date (epub): 2/2017AbstractAMP-activated
obesity 938 of these data is interesting from a therapeutic point of view as several agents with potential anti- obesity and/or antidiabetic effects, some currently in clinical use, such as nicotine, metformin and liraglutide
obesity 1865 of Santiago de Compostela, Spain. His research has focused on the regulation of energy balance and obesity , with his current interest on hypothalamic AMPK and energy sensing in the modulation of energy balance
obesity 11051 models display divergent phenotypes in terms of energy balance; while AMPKα2-POMC KO mice developed obesity due to hyperphagia, AMPKα2-AgRP KO mice developed an age-dependent lean phenotype ([39]). However,
obesity 12874 [65]). In contrast, antipsychotic drugs (APDs), such as olanzapine, well known for their orexigenic and obesity -prone properties, activate hypothalamic AMPK ([66], [67], [68], [69]). Overall, the evidence suggest
obesity 13044 [68], [69]). Overall, the evidence suggest that central AMPK is a potential target for the treatment of obesity , an idea that is reinforced by AMPK’s effects on energy expenditure ([40], [41], [42], [43], [44],
obesity 16549 context, recent data have also indicated that VMH AMPK could be an interesting target for the treatment of obesity . For example, nicotine, the main bioactive compound of tobacco, stimulates thermogenesis and weight
obesity 17347 a potential therapeutic target in metabolic diseases involving impaired eating behaviors, including obesity , T2D and some lipodystrophies. Although activation of AMPK can be expected to lead to a reduction of
obesity 21853 ([113], [115]).It is notable that patients with metabolic disorders, such as T2D, insulin resistance and obesity are at an increased risk of developing cancer ([116]). Since AMPK activation inhibits anabolism leading
obesity 23480 mitophagy during mitotic arrest ([11]).Is hypothalamic AMPK a realistic therapeutic target against obesity ?Obesity causes thousands of deaths per year worldwide, directly and indirectly due to comorbidities
obesity 24852 review see ([87]). However, central activation of AMPK would not give the best outcome in treatment for obesity as it would increase feeding while decrease BAT thermogenesis due to its differential regulation in

You must be authorized to submit a review.